Regencell Bioscience Holdings Limited
HKFinancials
Valuation Metrics
Regencell Bioscience Holdings Limited's Market Cap is $3.10B. At end of 2025 it was $10.38B. Ranked #1561 of 3,114 in US market (top 50%), #543 of 1,472 on NASDAQ (top 37%), #90 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.10B | US#1,561/3,114 Sec#90/265 |
| Revenue | $0.00 | US#2,862/3,114 Sec#193/265 |
| Net Income | $-4M | US—/3,114 Sec—/265 |
| Total Assets | $6M | US#3,091/3,114 Sec#265/265 |
| Net Assets | $5M | US#2,910/3,114 Sec#239/265 |
| Employees | 10 | US#2,771/3,114 Sec#221/265 |
| Value | ||
| P/B | 638.42x | US#2,912/3,114 Sec#239/265 |
| FCF Yield | -0.11% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -73.75% | US#2,754/3,114 Sec#192/265 |
| ROA | -62.27% | US#3,017/3,114 Sec#231/265 |
| Financial Health | ||
| Debt Ratio | 18.42% | US#204/3,114 Sec#73/265 |
| Total Debt | $544415.00 | US#2,986/3,114 Sec#250/265 |
| FCF | $-3M | US#2,330/3,114 Sec#88/265 |
| Cash | $2M | US#3,045/3,114 Sec#263/265 |
| Current Ratio | 7.39x | US#334/3,114 Sec#103/265 |
| Performance | ||
| 1Y Return | -62.31% | US#2,907/3,114 Sec#240/265 |
| 1M Return | -7.99% | US#130/3,114 Sec#15/265 |
| From 52W High | -90.91% | US#3,099/3,114 Sec#260/265 |
| 1Y MDD | -90.96% | US#3,107/3,114 Sec#260/265 |
| Trading | ||
| Volume | 71,011 shares | US#2,461/3,114 Sec#241/265 |
| Trading Value | $460861.00 | US#2,896/3,114 Sec#242/265 |
| Per Share | ||
| EPS | $-0.01 | US—/3,114 Sec—/265 |
| BPS | $0.01 | US#2,802/3,114 Sec#235/265 |
Company Info
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.